Literature DB >> 20972726

Exogenous Cushing's syndrome due to topical corticosteroid application: case report and review literature.

Therdpong Tempark1, Voraluk Phatarakijnirund, Susheera Chatproedprai, Suttipong Watcharasindhu, Vichit Supornsilchai, Siriwan Wananukul.   

Abstract

Prolonged use of topical corticosteroids causes systemic adverse effects including Cushing's syndrome and hypothalamic-pituitary-adrenal (HPA) axis suppression, which is less common than that of the oral or parenteral route. At least 43 cases with iatrogenic Cushing syndrome from very potent topical steroid usage (Clobetasol) in children and adult have been published over the last 35 years particularly in developing countries. In children group (n = 22), most are infants with diaper dermatitis and two cases who had started topical application at a very early age and died from severe disseminated CMV infection. For the adult group (n = 21), the most common purpose of steroid use was for treatment of Psoriasis. The recovery period of HPA axis suppression was 3.49 ± 2.92 and 3.84 ± 2.51 months in children and adult, respectively. We report on an 8-month-old female infant who developed Cushing's syndrome and adrenal insufficiency after diaper dermatitis treatment through the misuse of Clobetasol without doctor's prescription. Physiologic dose of hydrocortisone was prescribed to prevent an adrenal crisis for 3 months and discontinued when HPA axis recovery was confirmed by normal morning cortisol and ACTH levels.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20972726     DOI: 10.1007/s12020-010-9393-6

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  42 in total

1.  Cushing's syndrome and severe adrenal suppression in patients treated with ritonavir and inhaled nasal fluticasone.

Authors:  F Chen; T Kearney; S Robinson; P T Daley-Yates; S Waldron; D R Churchill
Journal:  Sex Transm Infect       Date:  1999-08       Impact factor: 3.519

2.  Cushing's syndrome secondary to topical corticosteroids abuse.

Authors:  Bahri Ermis; Rahmi Ors; Ayhan Tastekin; Behzat Ozkan
Journal:  Clin Endocrinol (Oxf)       Date:  2003-06       Impact factor: 3.478

3.  Unrecognised Cushing's syndrome and adrenal suppression due to topical clobetasol propionate.

Authors:  C A Young; I R Williams; I A MacFarlane
Journal:  Br J Clin Pract       Date:  1991

4.  Erythrodermic psoriasis associated with hyperuricemia and Iatrogenic Cushing's syndrome due to topical corticosteroid therapy.

Authors:  T Ohnishi; T Suzuki; S Watanabe; H Takahashi
Journal:  Int J Dermatol       Date:  1996-05       Impact factor: 2.736

5.  Hypothalamic-pituitary-adrenal function and glucocorticoid sensitivity in atopic dermatitis.

Authors:  J A Ellison; L Patel; D W Ray; T J David; P E Clayton
Journal:  Pediatrics       Date:  2000-04       Impact factor: 7.124

6.  Fatal disseminated cytomegalovirus infection in an infant with Cushing's syndrome caused by topical steroid.

Authors:  Ayla Guven; Sule Karadeniz; Oguz Aydin; Mehtap Akbalik; Murat Aydin
Journal:  Horm Res       Date:  2005-08-02

7.  Observations on the systemic effect of topical clobetasol propionate (Dermovate).

Authors:  J A Carruthers; P J August; R C Staughton
Journal:  Br Med J       Date:  1975-10-25

Review 8.  Adverse effects of topical glucocorticosteroids.

Authors:  Ulrich R Hengge; Thomas Ruzicka; Robert A Schwartz; Michael J Cork
Journal:  J Am Acad Dermatol       Date:  2006-01       Impact factor: 11.527

9.  Endocrine complications of topical and intralesional corticosteroid therapy.

Authors:  J A Curtis; E Cormode; B Laski; J Toole; N Howard
Journal:  Arch Dis Child       Date:  1982-03       Impact factor: 3.791

10.  An infantile Cushing syndrome due to misuse of topical steroid.

Authors:  Zeynep Siklar; Ilknur Bostanci; Ozlem Atli; Yildiz Dallar
Journal:  Pediatr Dermatol       Date:  2004 Sep-Oct       Impact factor: 1.588

View more
  28 in total

1.  Consequences of low birth weight, maternal illiteracy and poor access to medical care in rural India: infantile iatrogenic Cushing syndrome.

Authors:  Sunil Karande
Journal:  BMJ Case Rep       Date:  2015-08-21

2.  Maximal Usage Trial: An Overview of the Design of Systemic Bioavailability Trial for Topical Dermatological Products.

Authors:  Edward Dennis Bashaw; Doanh C Tran; Chinmay G Shukla; Xiaomei Liu
Journal:  Ther Innov Regul Sci       Date:  2014-06-27       Impact factor: 1.778

3.  Consequences of systemic absorption of topical glucocorticoids.

Authors:  Lynnette K Nieman
Journal:  J Am Acad Dermatol       Date:  2011-07       Impact factor: 11.527

Review 4.  [Diaper dermatitis].

Authors:  R Fölster-Holst; M Buchner; E Proksch
Journal:  Hautarzt       Date:  2011-09       Impact factor: 0.751

5.  Topical hesperidin prevents glucocorticoid-induced abnormalities in epidermal barrier function in murine skin.

Authors:  George Man; Theodora M Mauro; Peggy L Kim; Melanie Hupe; Yongjiao Zhai; Richard Sun; Debbie Crumrine; Carolyn Cheung; Almudena Nuno-Gonzalez; Peter M Elias; Mao-Qiang Man
Journal:  Exp Dermatol       Date:  2014-07-31       Impact factor: 3.960

6.  [Significance of therapy planning].

Authors:  J Wohlrab
Journal:  Hautarzt       Date:  2014-03       Impact factor: 0.751

7.  Linear growth arrest without weight gain due to overuse of topical clobetasol.

Authors:  Zahra Razavi; Milad Sanginabadi
Journal:  Oman Med J       Date:  2014-11

Review 8.  Managing Cushing's disease: the state of the art.

Authors:  Annamaria Colao; Marco Boscaro; Diego Ferone; Felipe F Casanueva
Journal:  Endocrine       Date:  2014-01-11       Impact factor: 3.633

9.  Osteoporotic vertebral fracture caused by topical corticosteroid abuse: A case report.

Authors:  Stefano Piaserico; Dennis Linder; Francesco Messina; Mauro Alaibac
Journal:  Exp Ther Med       Date:  2019-07-30       Impact factor: 2.447

10.  Cushing syndrome after bilateral lensectomy.

Authors:  Karin Sofia Scherrer; Marcus Weitz; Johannes Eisenack; Béatrice Truffer; Daniel Konrad
Journal:  Eur J Pediatr       Date:  2014-12-24       Impact factor: 3.183

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.